Elevation of serum KL-6 levels in 3 patients with rheumatoid arthritis treated with adalimumab

Abstract We describe 3 cases of rheumatoid arthritis presenting with elevated serum KL-6 levels during treatment with adalimumab, which was discontinued because of suspected onset of complications. However, no complications were observed following discontinuation despite comprehensive assessments, a...

Full description

Saved in:
Bibliographic Details
Published inModern rheumatology Vol. 22; no. 1; pp. 147 - 151
Main Authors Koiwa, Masahito, Goto, Susumu, Takenouchi, Kenji, Takahasi, Kenji, Kamada, Toshikazu, Nakamura, Hiroshi
Format Journal Article
LanguageEnglish
Published United States Informa Healthcare 01.02.2012
Subjects
Adalimumab
Aged
Antibodies, Monoclonal, Humanized - adverse effects
Antirheumatic Agents - adverse effects
Arthritis, Rheumatoid - blood
Arthritis, Rheumatoid - diagnosis
Arthritis, Rheumatoid - drug therapy
Communicable Diseases - diagnosis
Diagnosis, Differential
Female
Humans
Lung Diseases - diagnosis
Middle Aged
Mucin-1 - blood
Withholding Treatment
Online AccessGet full text

Cover

More Information
Summary:Abstract We describe 3 cases of rheumatoid arthritis presenting with elevated serum KL-6 levels during treatment with adalimumab, which was discontinued because of suspected onset of complications. However, no complications were observed following discontinuation despite comprehensive assessments, and KL-6 levels subsequently returned to baseline levels. In our institutes, 3 out of 29 cases treated with adalimumab showed elevated KL-6 levels. The baseline levels were 445, 347, and 547 U/ml, while the peak levels were 1010, 546, and 2007 U/ml, respectively. The elevated KL-6 levels seem to have been innocuous; nevertheless, further careful observation is deemed necessary.
ISSN:1439-7595
1439-7609
DOI:10.3109/s10165-011-0483-y